Noopept vs AICAR
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Noopept is a potent dipeptide-derived nootropic from Russia, structurally related to piracetam but estimated to be 1,000 times more potent by mass. It enhances memory consolidation, learning, and recall while providing neuroprotection via BDNF and NGF upregulation.
- AICAR is a cell-permeable AMP analog that activates AMPK (AMP-activated protein kinase) — the master metabolic switch that triggers fat burning, mitochondrial biogenesis, and adaptations normally only achieved through exercise. It has been called the 'exercise in a pill' compound.
- Half-Life
- ~5–10 minutes but metabolite (CPG) effects last hours
- ~2–3 hours
- Admin Route
- Oral, Sublingual, Intranasal
- SubQ, IV
- Research
- —
- —
- Typical Dose
- 10–30 mg
- 25–50 mg
- Frequency
- 1–2x daily
- 3–5 times per week
- Key Benefits
- Enhances memory formation and recall
- Improves learning speed and cognitive processing
- Neuroprotective via BDNF/NGF upregulation
- Anxiolytic at low-to-moderate doses
- Improves verbal fluency and information processing
- Antioxidant (reduces oxidative damage in neurons)
- May improve cognitive symptoms of mild cognitive impairment
- AMPK activation mimics aerobic exercise adaptations
- Increased fat oxidation and endurance
- Mitochondrial biogenesis (PGC-1alpha)
- Improved insulin sensitivity and glucose metabolism
- Anti-inflammatory effects
- Potential cardiac protection during ischemia
- Synergistic with actual exercise training
- Reduces hepatic glucose production
- Side Effects
- Headaches (choline depletion — pair with choline source)
- Irritability or anxiety at high doses
- Overstimulation
- Rare: brain fog with chronic use
- +1 more
- Hypoglycemia risk
- Lactic acidosis at high doses (animal data)
- Injection site irritation
- Stacks With
- —
- —